A citation-based method for searching scientific literature

Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Mikkel Wiberg, Niels H Brandt-Jacobsen, Peter Gæde, Peter Rossing, Jens Faber, Silvio E Inzucchi, Finn Gustafsson, Caroline Kistorp. J Am Heart Assoc 2021
Times Cited: 4







List of co-cited articles
19 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
75

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
75

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
200
75

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial.
Katrine M Lauritsen, Bent R R Nielsen, Lars P Tolbod, Mogens Johannsen, Jakob Hansen, Troels K Hansen, Henrik Wiggers, Niels Møller, Lars C Gormsen, Esben Søndergaard. Diabetes 2021
14
50

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Mikkel Wiberg, Niels Høgh Brandt, Peter Haulund Gæde, Peter Rossing,[...]. BMJ Open 2019
3
66

Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus.
Takayuki Kawata, Masao Daimon, Sakiko Miyazaki, Ryoko Ichikawa, Masaki Maruyama, Shuo-Ju Chiang, Chiharu Ito, Fumihiko Sato, Hirotaka Watada, Hiroyuki Daida. Cardiovasc Diabetol 2015
37
50

Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
Viviany R Taqueti, Scott D Solomon, Amil M Shah, Akshay S Desai, John D Groarke, Michael T Osborne, Jon Hainer, Courtney F Bibbo, Sharmila Dorbala, Ron Blankstein,[...]. Eur Heart J 2018
215
50

Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Matthew Griffin, Veena S Rao, Juan Ivey-Miranda, James Fleming, Devin Mahoney, Christopher Maulion, Nisha Suda, Krishmita Siwakoti, Tariq Ahmad, Daniel Jacoby,[...]. Circulation 2020
104
50


Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
Kåre I Birkeland, Johan Bodegard, Jan W Eriksson, Anna Norhammar, Hermann Haller, Gerard C M Linssen, Amitava Banerjee, Marcus Thuresson, Suguru Okami, Elena Garal-Pantaler,[...]. Diabetes Obes Metab 2020
34
50

Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes.
Bernt J von Scholten, Philip Hasbak, Thomas E Christensen, Adam A Ghotbi, Andreas Kjaer, Peter Rossing, Tine W Hansen. Diabetologia 2016
43
50

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/- mice.
Damilola D Adingupu, Sven O Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan, Ann-Cathrine Jönsson-Rylander. Cardiovasc Diabetol 2019
60
50

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Roberto M Lang, Luigi P Badano, Victor Mor-Avi, Jonathan Afilalo, Anderson Armstrong, Laura Ernande, Frank A Flachskampf, Elyse Foster, Steven A Goldstein, Tatiana Kuznetsova,[...]. Eur Heart J Cardiovasc Imaging 2015
50

Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
Tamique Mason, Otavio R Coelho-Filho, Subodh Verma, Biswajit Chowdhury, Fei Zuo, Adrian Quan, Kevin E Thorpe, Christopher Bonneau, Hwee Teoh, Richard E Gilbert,[...]. JACC Cardiovasc Imaging 2021
16
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
986
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Carlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez,[...]. J Am Coll Cardiol 2021
95
50

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
Sanjiv J Shah, Carolyn S P Lam, Sara Svedlund, Antti Saraste, Camilla Hage, Ru-San Tan, Lauren Beussink-Nelson, Ulrika Ljung Faxén, Maria Lagerström Fermer, Malin A Broberg,[...]. Eur Heart J 2018
185
25

Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy.
Rory Hachamovitch, Alan Rozanski, Leslee J Shaw, Gregg W Stone, Louise E J Thomson, John D Friedman, Sean W Hayes, Ishac Cohen, Guido Germano, Daniel S Berman. Eur Heart J 2011
317
25

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova,[...]. PLoS One 2014
162
25

Quantification of myocardial blood flow with 82Rb dynamic PET imaging.
Mireille Lortie, Rob S B Beanlands, Keiichiro Yoshinaga, Ran Klein, Jean N Dasilva, Robert A DeKemp. Eur J Nucl Med Mol Imaging 2007
267
25

Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes.
Marcel H A Muskiet, Erik Jm van Bommel, Daniël H van Raalte. Lancet Diabetes Endocrinol 2016
24
25

Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.
Kathryn Dryer, Mark Gajjar, Nikhil Narang, Margaret Lee, Jonathan Paul, Atman P Shah, Sandeep Nathan, Javed Butler, Charles J Davidson, William F Fearon,[...]. Am J Physiol Heart Circ Physiol 2018
52
25

Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia.
Stephen E Sherman, Gillian I Bell, Hwee Teoh, Mohammed Al-Omran, Kim A Connelly, Deepak L Bhatt, David A Hess, Subodh Verma. JACC Basic Transl Sci 2018
17
25





Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization.
Hana E Baker, Alexander M Kiel, Samuel T Luebbe, Blake R Simon, Conner C Earl, Ajit Regmi, William C Roell, Kieren J Mather, Johnathan D Tune, Adam G Goodwill. Basic Res Cardiol 2019
29
25


Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC.
Venkatesh L Murthy, Timothy M Bateman, Rob S Beanlands, Daniel S Berman, Salvador Borges-Neto, Panithaya Chareonthaitawee, Manuel D Cerqueira, Robert A deKemp, E Gordon DePuey, Vasken Dilsizian,[...]. J Nucl Med 2018
79
25

Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health.
Thomas H Schindler, Heinrich R Schelbert, Alessandra Quercioli, Vasken Dilsizian. JACC Cardiovasc Imaging 2010
245
25

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Bowen Lin, Nobutaka Koibuchi, Yu Hasegawa, Daisuke Sueta, Kensuke Toyama, Ken Uekawa, MingJie Ma, Takashi Nakagawa, Hiroaki Kusaka, Shokei Kim-Mitsuyama. Cardiovasc Diabetol 2014
203
25

Reduced Myocardial Perfusion Reserve in Type 2 Diabetes Is Caused by Increased Perfusion at Rest and Decreased Maximal Perfusion During Stress.
Martin H Sørensen, Annemie S Bojer, Julie R N Pontoppidan, David A Broadbent, Sven Plein, Per L Madsen, Peter Gæde. Diabetes Care 2020
10
25

Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus.
Venkatesh L Murthy, Masanao Naya, Courtney R Foster, Mariya Gaber, Jon Hainer, Josh Klein, Sharmila Dorbala, Ron Blankstein, Marcelo F Di Carli. Circulation 2012
299
25

Global Coronary Flow Reserve Measured During Stress Cardiac Magnetic Resonance Imaging Is an Independent Predictor of Adverse Cardiovascular Events.
Raksha Indorkar, Raymond Y Kwong, Simone Romano, Brent E White, Richard C Chia, Michael Trybula, Kaleigh Evans, Chetan Shenoy, Afshin Farzaneh-Far. JACC Cardiovasc Imaging 2019
46
25

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Alexander J M Brown, Stephen Gandy, Rory McCrimmon, John Graeme Houston, Allan D Struthers, Chim C Lang. Eur Heart J 2020
48
25

Reduced Myocardial Flow in Heart Failure Patients With Preserved Ejection Fraction.
Kajenny Srivaratharajah, Thais Coutinho, Robert deKemp, Peter Liu, Haissam Haddad, Ellamae Stadnick, Ross A Davies, Sharon Chih, Girish Dwivedi, Ann Guo,[...]. Circ Heart Fail 2016
64
25

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Sherif F Nagueh, Otto A Smiseth, Christopher P Appleton, Benjamin F Byrd, Hisham Dokainish, Thor Edvardsen, Frank A Flachskampf, Thierry C Gillebert, Allan L Klein, Patrizio Lancellotti,[...]. J Am Soc Echocardiogr 2016
25

Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction.
Mads Ersbøll, Nana Valeur, Ulrik Madvig Mogensen, Mads Jønsson Andersen, Jacob Eifer Møller, Eric J Velazquez, Christian Hassager, Peter Søgaard, Lars Køber. J Am Coll Cardiol 2013
240
25

Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Michele Correale, Renata Petroni, Stefano Coiro, Elena-Laura Antohi, Francesco Monitillo, Marta Leone, Marco Triggiani, Shiro Ishihara, Hans-Dirk Dungen, Chaudhry M S Sarwar,[...]. Heart Fail Rev 2021
2
50

Prognostic significance of left ventricular mass change during treatment of hypertension.
Richard B Devereux, Kristian Wachtell, Eva Gerdts, Kurt Boman, Markku S Nieminen, Vasilios Papademetriou, Jens Rokkedal, Katherine Harris, Peter Aurup, Björn Dahlöf. JAMA 2004
601
25


Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Massar Omar, Jesper Jensen, Mulham Ali, Peter H Frederiksen, Caroline Kistorp, Lars Videbæk, Mikael Kjær Poulsen, Christian D Tuxen, Sören Möller, Finn Gustafsson,[...]. JAMA Cardiol 2021
24
25

Myocardial composition and function in diabetes. The effects of chronic insulin use.
T J Regan, C F Wu, C K Yeh, H A Oldewurtel, B Haider. Circ Res 1981
142
25

Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries.
Katherine H Chau, Pamela S Douglas, Philippe Pibarot, Rebecca T Hahn, Omar K Khalique, Wael A Jaber, Paul Cremer, Neil J Weissman, Federico M Asch, Yiran Zhang,[...]. J Am Coll Cardiol 2020
29
25

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
266
25

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Kim A Connelly, Yanling Zhang, Jean-François Desjardins, Linda Nghiem, Aylin Visram, Sri N Batchu, Verra G Yerra, Golam Kabir, Kerri Thai, Andrew Advani,[...]. Cardiovasc Diabetol 2020
20
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.